Beam Anticipates Pfizer Deal Will Lead To Additional Partnerships
The $300m upfront payment should provide considerable runway for the base-editing company, which also plans multiple IND filings and enrolling the first patient in its sickle cell study this year.
You may also be interested in...
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
With cash to spend and a patent cliff to overcome starting in 2025, Pfizer is expected to be a prolific deal-maker in 2022.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.